2. Teramachi J, Kurihara N, Windle J, et al. Expression of measles virus nucleocapsid protein (MVNP) gene in osteoclasts induces coupling factors that stimulate bone formation In: Poster sessions presented at: ASBMR 2012 Annual Meeting. 2012 October 12-15; Minesota, USA.
3. Basle M, Minard MF, Rebel A. Structure and ultrastructure of osteoblasts and of the osteoid tissue in Paget's disease of bone (author's transl). Pathol Biol (Paris) 1978;26:475-479.
4. Zajac AJ, Phillips PE. Paget's disease of bone: clinical features and treatment. Clin Exp Rheumatol 1985;3:75-88.
5. Chung PY, Van Hul W. Paget's disease of bone: evidence for complex pathogenetic interactions. Semin Arthritis Rheum 2012;41:619-641.
6. Tiegs RD, Lohse CM, Wollan PC, et al. Long-term trends in the incidence of Paget's disease of bone. Bone 2000;27:423-427.
7. Morales-Piga AA, Rey-Rey JS, Corres-González J, et al. Frequency and characteristics of familial aggregation of Paget's disease of bone. J Bone Miner Res 1995;10:663-670.
8. Siris ES, Jacobs TP, Canfield RE. Paget's disease of bone. Bull N Y Acad Med 1980;56:285-304.
9. Roodman GD. Insights into the pathogenesis of Paget's disease. Ann N Y Acad Sci 2010;1192:176-180.
10. Rogov V, Dotsch V, Johansen T, et al. Interactions between autophagy receptors and ubiquitin-like proteins form the molecular basis for selective autophagy. Mol Cell 2014;53:167-178.
13. Morissette J, Laurin N, Brown JP. Sequestosome 1: mutation frequencies, haplotypes, and phenotypes in familial Paget's disease of bone. J Bone Miner Res 2006;21(Suppl 2):P38-P44.
14. Bolland MJ, Tong PC, Naot D, et al. Delayed development of Paget's disease in offspring inheriting SQSTM1 mutations. J Bone Miner Res 2007;22:411-415.
15. Gennari L, Gianfrancesco F, Di Stefano M, et al. SQSTM1 gene analysis and gene-environment interaction in Paget's disease of bone. J Bone Miner Res 2010;25:1375-1384.
16. Leach RJ, Singer FR, Ench Y, et al. Clinical and cellular phenotypes associated with sequestosome 1 (SQSTM1) mutations. J Bone Miner Res 2006;21(Suppl 2):P45-P50.
17. Doyle T, Gunn J, Anderson G, et al. Paget's disease in New Zealand: evidence for declining prevalence. Bone 2002;31:616-619.
18. van Staa TP, Selby P, Leufkens HG, et al. Incidence and natural history of Paget's disease of bone in England and Wales. J Bone Miner Res 2002;17:465-471.
19. Poór G, Donath J, Fornet B, et al. Epidemiology of Paget's disease in Europe: the prevalence is decreasing. J Bone Miner Res 2006;21:1545-1549.
24. Chung PY, Beyens G, Riches PL, et al. Genetic variation in the TNFRSF11A gene encoding RANK is associated with susceptibility to Paget's disease of bone. J Bone Miner Res 2010;25:2592-2605.
25. Daroszewska A, Hocking LJ, McGuigan FE, et al. Susceptibility to Paget's disease of bone is influenced by a common polymorphic variant of osteoprotegerin. J Bone Miner Res 2004;19:1506-1511.
28. Kachaner D, Génin P, Laplantine E, et al. Toward an integrative view of Optineurin functions. Cell Cycle 2012;11:2808-2818.
30. Kajiho H, Saito K, Tsujita K, et al. RIN3: a novel Rab5 GEF interacting with amphiphysin II involved in the early endocytic pathway. J Cell Sci 2003;116:4159-4168.
37. Mills BG, Singer FR, Weiner LP, et al. Evidence for both respiratory syncytial virus and measles virus antigens in the osteoclasts of patients with Paget's disease of bone. Clin Orthop Relat Res 1984;303-311.
38. Gordon MT, Mee AP, Sharpe PT. Paramyxoviruses in Paget's disease. Semin Arthritis Rheum 1994;23:232-234.
39. Mee AP, Dixon JA, Hoyland JA, et al. Detection of canine distemper virus in 100% of Paget's disease samples by in situ-reverse transcriptase-polymerase chain reaction. Bone 1998;23:171-175.
41. Kurihara N, Reddy SV, Menaa C, et al. Osteoclasts expressing the measles virus nucleocapsid gene display a pagetic phenotype. J Clin Invest 2000;105:607-614.
42. Gordon MT, Mee AP, Anderson DC, et al. Canine distemper virus transcripts sequenced from pagetic bone. Bone Miner 1992;19:159-174.
44. Kurihara N, Hiruma Y, Zhou H, et al. Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease. J Clin Invest 2007;117:133-142.
46. Kurihara N, Zhou H, Reddy SV, et al. Expression of measles virus nucleocapsid protein in osteoclasts induces Paget's disease-like bone lesions in mice. J Bone Miner Res 2006;21:446-455.
47. Roodman GD. Interleukin-6: an osteotropic factor? J Bone Miner Res 1992;7:475-478.
49. Teramachi J, Zhou H, Subler MA, et al. Increased IL-6 Expression in Osteoclasts is Necessary but not Sufficient for the Development of Paget's Disease of Bone. J Bone Miner Res 2013.
50. Neale SD, Smith R, Wass JA, et al. Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin D(3) and RANKL. Bone 2000;27:409-416.
51. Mengus G, Gangloff YG, Carré L, et al. The human transcription factor IID subunit human TATA-binding protein-associated factor 28 interacts in a ligand-reversible manner with the vitamin D(3) and thyroid hormone receptors. J Biol Chem 2000;275:10064-10071.
53. Kurihara N, Reddy SV, Araki N, et al. Role of TAFII-17, a VDR binding protein, in the increased osteoclast formation in Paget's Disease. J Bone Miner Res 2004;19:1154-1164.
54. Teramachi J, Hiruma Y, Ishizuka S, et al. Role of ATF7-TAF12 interactions in the vitamin D response hypersensitivity of osteoclast precursors in Paget's disease. J Bone Miner Res 2013;28:1489-1500.
55. Ye H, Arron JR, Lamothe B, et al. Distinct molecular mechanism for initiating TRAF6 signalling. Nature 2002;418:443-447.
56. Besse A, Lamothe B, Campos AD, et al. TAK1-dependent signaling requires functional interaction with TAB2/TAB3. J Biol Chem 2007;282:3918-3928.
57. Durán A, Serrano M, Leitges M, et al. The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev Cell 2004;6:303-309.
58. Chamoux E, McManus S, Laberge G, et al. Involvement of kinase PKC-zeta in the p62/p62(P392L)-driven activation of NF-kappaB in human osteoclasts. Biochim Biophys Acta 2013;1832:475-484.
59. Sanz L, Sanchez P, Lallena MJ, et al. The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation. EMBO J 1999;18:3044-3053.
61. Nagabhushana A, Bansal M, Swarup G. Optineurin is required for CYLD-dependent inhibition of TNFalpha-induced NF-kappaB activation. PLoS One 2011;6:e17477
62. Wang FM, Sarmasik A, Hiruma Y, et al. Measles virus nucleocapsid protein, a key contributor to Paget's disease, increases IL-6 expression via down-regulation of FoxO3/Sirt1 signaling. Bone 2013;53:269-276.
63. Keller ET, Chang C, Ershler WB. Inhibition of NFkappaB activity through maintenance of IkappaBalpha levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter. J Biol Chem 1996;271:26267-26275.
64. Hu HM, Tian Q, Baer M, et al. The C/EBP bZIP domain can mediate lipopolysaccharide induction of the proinflammatory cytokines interleukin-6 and monocyte chemoattractant protein-1. J Biol Chem 2000;275:16373-16381.
65. Sharma S, tenOever BR, Grandvaux N, et al. Triggering the interferon antiviral response through an IKK-related pathway. Science 2003;300:1148-1151.
67. Nagy ZB, Gergely P, Donáth J, et al. Gene expression profiling in Paget's disease of bone: upregulation of interferon signaling pathways in pagetic monocytes and lymphocytes. J Bone Miner Res 2008;23:253-259.
68. Adli M, Baldwin AS. IKK-i/IKKepsilon controls constitutive, cancer cell-associated NF-kappaB activity via regulation of Ser-536 p65/RelA phosphorylation. J Biol Chem 2006;281:26976-26984.
69. Buss H, Dorrie A, Schmitz ML, et al. Constitutive and interleukin-1-inducible phosphorylation of p65 NF-{kappa}B at serine 536 is mediated by multiple protein kinases including I{kappa}B kinase (IKK)-{alpha}, IKK{beta}, IKK{epsilon}, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription. J Biol Chem 2004;279:55633-55643.
70. Sun Q, Sammut B, Wang FM, et al. TBK1 mediates critical effects of measles virus nucleocapsid protein (MVNP) on pagetic osteoclast formation. J Bone Miner Res 2014;29:90-102.
71. Greene WC, Chen LF. Regulation of NF-kappaB action by reversible acetylation. Novartis Found Symp 2004;259:208-217. discussion 18-25.
72. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857-868.
73. Luron L, Saliba D, Blazek K, et al. FOXO3 as a new IKK-epsilon-controlled check-point of regulation of IFN-beta expression. Eur J Immunol 2012;42:1030-1037.
74. Yang JY, Zong CS, Xia W, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 2008;10:138-148.
75. Ishizuka H, García-Palacios V, Lu G, et al. ADAM8 enhances osteoclast precursor fusion and osteoclast formation in vitro and in vivo. J Bone Miner Res 2011;26:169-181.
76. Xing L, Xiu Y, Boyce BF. Osteoclast fusion and regulation by RANKL-dependent and independent factors. World J Orthop 2012;3:212-222.
77. Sarmasik A, Hiruma Y, Okumura S, et al. Measles virus nucleoprotein (MVNP) enhances NFATcl activation during osteoclastogenesis in Paget's disease. J Bone Miner Res 2007;22(Suppl 1):S221.
80. Zhao C, Irie N, Takada Y, et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 2006;4:111-121.
81. Hayashi M, Nakashima T, Taniguchi M, et al. Osteoprotection by semaphorin 3A. Nature 2012;485:69-74.
82. Zhang M, Xuan S, Bouxsein ML, et al. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem 2002;277:44005-44012.
83. Kurihara N, Teramachi J, Kitagawa Y, et al. IGF1 contributes to the increased bone formation induced by measles virus nucleocapsid protein expressed by osteoclasts in Paget's bone disease In: Poster sessions presented at: ASBMR 2013 Annual Meeting. 2013 October 4-7; Baltimore, MD, USA.
85. Zhang X, Sobue T, Hurley MM. FGF-2 increases colony formation, PTH receptor, and IGF-1 mRNA in mouse marrow stromal cells. Biochem Biophys Res Commun 2002;290:526-531.
86. Sundaram K, Senn J, Reddy SV. SOCS-1/3 participation in FGF-2 signaling to modulate RANK ligand expression in paget's disease of bone. J Cell Biochem 2013;114:2032-2038.